Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — J.P. Morgan Healthcare Conference 2025
30 slides from Eyepoint's conference presentation, Jan 13, 2025
Slide 1: J.P. Morgan Healthcare Conference Presentation
J.P. Morgan Healthcare Conference Presentation January 14, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1
Slide 2: Legal Disclaimers
Legal Disclaimers ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate
Slide 3: The Leader in Sustained Release Drug Delivery for Retinal Disease
The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Most robust dataset in wet AMD among all sustained delivery programs Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Strong balance sheet with ~$370M in ca
Slide 4: Pipeline Leveraging Durasert E Drug Delivery Technology
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. wet AMD, wet age-related macular degeneration; DME, diabetic macular edema; PK, pharmacokinetic; GA, geographic atrophy Pipeline Leveraging Durasert E™ Drug Delivery Technology trial underway non-clinical Durasert E™ Programs Indication Disco
Slide 5: Durasert E Technology Sustained-Release Drug Delivery
IVT, intravitreal DURASERT E™ TECHNOLOGY Sustained-Release Drug Delivery Standard in-office IVT injection Continuous dosing Zero-order kinetics drug release Bioerodible Durasert E™: Solid injectable insert Drug formulated within a bioerodible matrix Designed to release drug load before matrix fully
Slide 6: Vorolanib is a Best-In-Class TKI that Selectively Inhibits all Forms of the VEGF Receptor
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Bakri SJ, et al. PLoS One. 2024;19(6):e0304782 [CC BY 4.0]. TKI tyrosine kinase inhibitor; AMD, age-related macular degeneration; Ang, angiopoietin; FGF(R), fibroblast growth factor (receptor); PDGF(R), platelet-derived growth factor (rece
Slide 7: DURAVYU: Vorolanib in Bioerodible Durasert E
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Immediately bioavailable – reaches therapeutic levels within hours Constant dosing – zero-order kinetics release for at least six months Controlled drug release – bioerodible matrix controls drug release; no free-floating drug Contains NO PEG
Slide 8: DURAVYU Demonstrated Positive Efficacy and Favorable Safety Across Multiple Trials
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials and Indications 1. Interim data as of October 1, 2024. Preliminary data which may differ from future results of the same trial, or different c
Slide 9: Phase 2 DAVIO 2 Positive Results in wet AMD as a 6-Month Maintenance Therapy
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Positive Results in wet AMD as a 6-Month Maintenance Therapy A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL
Slide 10: DAVIO 2 Randomized, Double-Masked, Aflibercept Controlled Clinical Trial
DAVIO 2 is Randomized, Double-Masked, Aflibercept Controlled* Clinical Trial to Assess Efficacy and Safety of DURAVYU at Two Doses ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Aflibercept on-label control required by FDA -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 DURAVYU 2
Slide 11: DURAVYU Phase 2 DAVIO 2 Clinical Trial Met All Endpoints
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Phase 2 DAVIO 2 Clinical Trial Met All Endpoints DAVIO 2 Endpoint 2mg dose 3mg dose R Primary: Non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Favorable safety profile1 No DURAVYU-related SAEs R Se
Slide 12: DURAVYU was Statistically Non-Inferior in Change in BCVA
+1.0* +1.3* +0.9* -0.5 -0.1 -0.5 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control *Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after DURAVYU injection 1 – AAO 2022
Slide 13: DURAVYU Treated Patients Showed Strong Anatomic Control
+10.6 um +17.8 um +5.4 um +11.2 um +21.2 um +11.1 um ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU Treated Patients Showed Strong Anatomic Control *Month 8 represents 6 months after DURAVYU injection MEAN CHANGE IN CST Aflibercept Month 9 Month 10 Month 11 Month 12 Aflibercept Af
Slide 14: Meaningful Supplement-Free Rates in Eyes Treated with DURAVYU
Meaningful Supplement-Free Rates in Eyes Treated with DURAVYU Support DURAVYU as a Potential 6-Month Treatment for Wet AMD ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *First visit patients are eligible to be supplemented **Month 8 represents 6 months post DURAVYU injection Summary of S
Slide 15: DURAVYU LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD NON-INFERIORITY VERSUS AN AFLIBERCEPT CONTROL
Slide 16: Phase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU
Phase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Demonstrate DURAVYU, when administered every six months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden ~400 patients per
Slide 17: DURAVYU in Wet AMD Phase 3 Pivotal Trial Design
DURAVYU™ in Wet AMD Phase 3 Pivotal Trial Design ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening D1 W4 W8 W12 W16 W24 W32 W84-W92 W20 W28 DURAVYU™ 2.7mg Aflibercept 2mg q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED DURAVYU™ DOSE AFLIBERCEPT q8W 1⁰ ENDPOIN
Slide 18: Exceptional Enrollment to Date Driven by Investigator and Patient Enthusiasm
Exceptional Enrollment to Date Driven by Significant Investigator and Patient Enthusiasm ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. June 2024 Final Phase 3 protocols October 2024 First patient in LUGANO trial dosed December 2024 First patient in LUCIA trial dosed 2H 2025 Expected full
Slide 19: Phase 2 VERONA Clinical Trial in DME – 16-Week Interim Results
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 VERONA Clinical Trial in DME – 16-Week Interim Results all patients Have completed the week 16 visit DME, diabetic macular edema Interim data as of October 1, 2024. Preliminary data which may differ from future results of the same tri
Slide 20: VERONA Phase 2 Randomized, Open-Label, Aflibercept Controlled Trial
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema; VEGF, vascular endothelial growth factor; BCVA, best corrected visual acuity; OCT, optical coherence tomography; CST, central subfield thickness DURAVYU dosing Visit Scheduled aflibercept injection Sham injection
Slide 21: VERONA: Baseline BCVA and CST Demonstrate Patients with Active DME
VERONA: Baseline BCVA and CST Demonstrate Patients with Active DME (CST >325μm) ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Aflibercept 2mg (n=6) DURAVYU 1.3mg (n=10) DURAVYU 2.7mg (n=11) Mean BCVA, ETDRS letters (range) 67.5 (57-73) 66.9 (53-75) 65.5 (46-75) Mean CST, μm (range) 400.3
Slide 22: VERONA: DURAVYU 2.7mg Clinically Meaningful Improvement in BCVA at 16 Weeks
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. VERONA: DURAVYU 2.7mg Demonstrated Clinically Meaningful Improvement in BCVA at 16 Weeks ~Six Letters Better vs. Aflibercept Control DURAVYU 2.7mg +5.7 Mean Change in BCVA vs Aflibercept DURAVYU 1.3mg +0.6 +3.8 +8.9 +3.2 MEAN CHANGE IN BCVA F
Slide 23: VERONA: Improved and Controlled Anatomy with DURAVYU 2.7mg
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. VERONA: Improved and Controlled Anatomy Demonstrated with DURAVYU 2.7mg and Mirror BCVA Results ~38 Microns Improved vs. Aflibercept Control Mean Change in CST vs Aflibercept DURAVYU 1.3mg -8.5 um -39.0 um -68.1 um -30.5 um MEAN CHANGE IN CST
Slide 24: VERONA: Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control
VERONA: Eyes Treated with DURAVYU had a Greater Proportion of Supplement-Free Eyes vs. Aflibercept Control at 16 Weeks ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Summary of Cumulative Supplement-Free Rates by Week* 100% 100% 100% *Time to aflibercept supplementation and supplement rat
Slide 25: VERONA: Positive Interim Data Supports DURAVYU as Potential Treatment for DME
VERONA: Positive Interim Data Supports DURAVYU as a Potential Treatment for DME Data support potential for vision improvement in DME as well as superior dosing intervals ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2.7MG EFFICACY 16-Week Results: Early and sustained BCVA improve
Slide 26: Commercial Manufacturing Facility Opened in October 2024
Commercial Manufacturing Facility Opened in October 2024 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. FDA, Federal Drug Administration; EMA, European Medicines Agency; cGMP, current good manufacturing practice Located in Northbridge, MA Built to US FDA and EU EMA standards 40,000sf cGMP
Slide 27: EYP-2301: razuprotafib in Durasert E
©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-2301: razuprotafib in Durasert E™ A sustained delivery tie-2 agonist for severe retinal diseases
Slide 28: EYP-2301: Razuprotafib in Durasert E is a Patented TIE-2 Agonist
EYP-2301: Razuprotafib in Durasert E™ is a Patented TIE-2 Agonist as a Potential New MOA for Treating Serious Retinal Diseases ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Heier et al. Retina, 2021;41:1-19. and Joussen et al. Eye 2021; 35:1305-1316.; 2. Hammes, et. Al – Diabetes.2011
Slide 29: The Leader in Sustained Release Drug Delivery for Retinal Disease
The Leader in Sustained Release Drug Delivery for Retinal Disease ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Most robust dataset in wet AMD among all sustained delivery programs Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Strong balance sheet with ~$370M in ca
Slide 30: J.P. Morgan Healthcare Conference Presentation
J.P. Morgan Healthcare Conference Presentation January 14, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint Pharmaceuticals — J.P. Morgan Healthcare Conference 2025 on 6ix